About Stelis Biosource
Stelis Biosource is a company based in Bengaluru (India) founded in 2012. Stelis Biosource has raised $125 million across 1 funding round from investors including TPG, RouteOne and Mankekar Family Office. The company has 1,425 employees as of May 31, 2025. Stelis Biosource operates in a competitive market with competitors including KBI Biopharma, Aldevron, Kemwell Biopharma, Eurogentec and Ovagen, among others.
- Headquarter Bengaluru, India
- Employees 1425 as on 31 May, 2025
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Stelis Biopharma Private Limited
- Date of Incorporation 16 May, 2012
- Jurisdiction Bangalore, Karnataka, India
-
Annual Revenue
$21.28 M (USD)325as on Mar 31, 2024
-
Net Profit
-$44.18 M (USD)12as on Mar 31, 2024
-
EBITDA
-$24.16 M (USD)34as on Mar 31, 2024
-
Total Equity Funding
$125 M (USD)
in 1 rounds
-
Latest Funding Round
$125 M (USD), Series C
Mar 19, 2021
-
Investors
TPG
& 4 more
-
Employee Count
1425
as on May 31, 2025
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Stelis Biosource
Stelis Biosource has successfully raised a total of $125M through 1 strategic funding round. The most recent funding activity was a Series C round of $125 million completed in March 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Stelis Biosource
Stelis Biosource has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include TPG, RouteOne and Mankekar Family Office.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Fund of funds focused on pre-seed and seed-stage companies
|
Locked | Locked | Locked | |
|
Single family office of Shivanand Shankar Mankekar, founder of manekar family office
|
Locked | Locked | Locked | |
|
Investment Firm
|
Locked | Locked | Locked |
Investor details for Stelis Biosource
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Stelis Biosource
Investment portfolio details for Stelis Biosource
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Stelis Biosource
Detailed financials for Stelis Biosource
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Stelis Biosource Comparisons
Peer comparison for Stelis Biosource
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Stelis Biosource
Stelis Biosource operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as KBI Biopharma, Aldevron, Kemwell Biopharma, Eurogentec and Ovagen, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Provider of protein formulation, process & cell line development, and cGMP services
|
|
| Locked | Locked | Locked |
Developer and custom manufacturer of nucleic acids, proteins and antibodies for research, clinical and commercial applications
|
|
| Locked | Locked | Locked |
Integrated biologics development and manufacturing are provided as a CDMO.
|
|
| Locked | Locked | Locked |
Oligonucleotides, peptides, and antibodies are developed and manufactured by Eurogentec.
|
|
| Locked | Locked | Locked |
Provider of germ-free and specific pathogen free production of eggs for vaccine and antibody manufacturing services
|
|
| Locked | Locked | Locked |
Precision fermentation services for biopharma and food are provided.
|
Detailed competitors of Stelis Biosource
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Stelis Biosource
Complete news archive for Stelis Biosource
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Stelis Biosource
Stelis Biosource was founded in 2012 and raised its 1st funding round 9 years after it was founded.
Stelis Biosource is headquartered in Bengaluru, India. It is registered at Bengaluru, Karnataka, India.
Joe Thomas is the current CEO of Stelis Biosource.
Stelis Biosource is a funded company, having raised a total of $125M across 1 funding round to date.
As of May 31, 2025, the latest employee count at Stelis Biosource is 1,425.
Annual revenue of Stelis Biosource is $21.28M as on Mar 31, 2024.
Stelis Biosource was established in 2012 in Bengaluru, India, as the CDMO division of Stelis Biopharma. Biopharmaceutical services are delivered across process development, scale-up in microbial and mammalian systems, downstream operations like chromatography and filtration, formulation for injectables, analytical methods including bioassays and stability testing, and cGMP manufacturing in certified facilities.
Stelis Biosource's top competitors include KBI Biopharma, Aldevron and Ovagen.
Stelis Biosource has 5 investors. Key investors include TPG, RouteOne, Mankekar Family Office, Think Investments, and GMS Holdings.